[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.130.145. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
August 17, 2011

Genomic Predictor of Survival After Chemotherapy for Breast Cancer

Author Affiliations
 

Letters Section Editor: Jody W. Zylke, MD, Senior Editor.

Author Affiliation: George Washington University, Washington, DC (hburke@gwu.edu).

JAMA. 2011;306(7):707-709. doi:10.1001/jama.2011.1148

To the Editor: Dr Hatzis and colleagues1 reported the creation of a genomic predictor that identifies patients with a high probability of survival following taxane-anthracycline chemotherapy for invasive breast cancer. Two issues require clarification.

First, how were the patients recruited for this study? What were the inclusion and exclusion criteria? How were patients selected for the taxane-anthracycline chemotherapy? Did the patients receive any neoadjuvant or other adjuvant therapy? Were the patients enrolled consecutively?

First Page Preview View Large
First page PDF preview
First page PDF preview
×